Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study
Abstract Background Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevale...
Saved in:
Published in | Open forum infectious diseases Vol. 10; no. 11; p. ofad517 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
01.11.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevalence of, and factors associated with, HCV RNA and treatment initiation among people enrolled in a state-wide pilot of people testing in the NSW DBS Pilot in New South Wales, Australia.
Methods
People at risk of HIV/HCV could participate via (1) self-registration online with a DBS collection kit delivered and returned by conventional postal service; or (2) assisted DBS sample collection at a community site or prison. Logistic regression was used to identify factors associated with detectable HCV RNA and treatment initiation within 6 months of testing.
Results
Between September 2017 and December 2020, 5960 people were tested for HCV (76% men, 35% Aboriginal and/or Torres Strait Islander, 55% recently injected drugs): 21% online self-registration, 34% assisted registration in the community, 45% assisted registration in prison. Fifteen percent had detectable HCV RNA (878/5960). Overall, 44% (n = 386/878) of people with current HCV initiated treatment within 6 months (13% online self-registration, 27% assisted registration in the community, 61% assisted registration in prison). Testing in prison compared with the community (adjusted odds ratio [aOR], 4.28; 95% CI, 3.04–6.03) was associated with increased odds of treatment initiation. Being a woman compared with a man (aOR, 0.68; 95% CI, 0.47–0.97) was associated with reduced treatment initiation.
Conclusions
The NSW DBS Pilot demonstrates the feasibility of using DBS to promote HCV testing and treatment in community and prison settings. |
---|---|
AbstractList | BackgroundDried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevalence of, and factors associated with, HCV RNA and treatment initiation among people enrolled in a state-wide pilot of people testing in the NSW DBS Pilot in New South Wales, Australia.MethodsPeople at risk of HIV/HCV could participate via (1) self-registration online with a DBS collection kit delivered and returned by conventional postal service; or (2) assisted DBS sample collection at a community site or prison. Logistic regression was used to identify factors associated with detectable HCV RNA and treatment initiation within 6 months of testing.ResultsBetween September 2017 and December 2020, 5960 people were tested for HCV (76% men, 35% Aboriginal and/or Torres Strait Islander, 55% recently injected drugs): 21% online self-registration, 34% assisted registration in the community, 45% assisted registration in prison. Fifteen percent had detectable HCV RNA (878/5960). Overall, 44% (n = 386/878) of people with current HCV initiated treatment within 6 months (13% online self-registration, 27% assisted registration in the community, 61% assisted registration in prison). Testing in prison compared with the community (adjusted odds ratio [aOR], 4.28; 95% CI, 3.04-6.03) was associated with increased odds of treatment initiation. Being a woman compared with a man (aOR, 0.68; 95% CI, 0.47-0.97) was associated with reduced treatment initiation.ConclusionsThe NSW DBS Pilot demonstrates the feasibility of using DBS to promote HCV testing and treatment in community and prison settings. Abstract Background Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a nonclinical setting. Large-scale evaluations are needed to understand how DBS testing can reduce HCV burden. This study estimated prevalence of, and factors associated with, HCV RNA and treatment initiation among people enrolled in a state-wide pilot of people testing in the NSW DBS Pilot in New South Wales, Australia. Methods People at risk of HIV/HCV could participate via (1) self-registration online with a DBS collection kit delivered and returned by conventional postal service; or (2) assisted DBS sample collection at a community site or prison. Logistic regression was used to identify factors associated with detectable HCV RNA and treatment initiation within 6 months of testing. Results Between September 2017 and December 2020, 5960 people were tested for HCV (76% men, 35% Aboriginal and/or Torres Strait Islander, 55% recently injected drugs): 21% online self-registration, 34% assisted registration in the community, 45% assisted registration in prison. Fifteen percent had detectable HCV RNA (878/5960). Overall, 44% (n = 386/878) of people with current HCV initiated treatment within 6 months (13% online self-registration, 27% assisted registration in the community, 61% assisted registration in prison). Testing in prison compared with the community (adjusted odds ratio [aOR], 4.28; 95% CI, 3.04–6.03) was associated with increased odds of treatment initiation. Being a woman compared with a man (aOR, 0.68; 95% CI, 0.47–0.97) was associated with reduced treatment initiation. Conclusions The NSW DBS Pilot demonstrates the feasibility of using DBS to promote HCV testing and treatment in community and prison settings. |
Author | Conway, Anna Stevens, Annabelle McNulty, Anna Prain, Bianca McGrath, Colette Murray, Carolyn Grebely, Jason Kingsland, Melanie Catlett, Beth Power, Cherie Cunningham, Philip Carrington, Nigel Starr, Mitchell Read, Phillip Lu, Heng |
Author_xml | – sequence: 1 givenname: Anna orcidid: 0000-0002-9082-9714 surname: Conway fullname: Conway, Anna email: a.conway@unsw.edu.au – sequence: 2 givenname: Annabelle surname: Stevens fullname: Stevens, Annabelle – sequence: 3 givenname: Carolyn surname: Murray fullname: Murray, Carolyn – sequence: 4 givenname: Bianca surname: Prain fullname: Prain, Bianca – sequence: 5 givenname: Cherie surname: Power fullname: Power, Cherie – sequence: 6 givenname: Anna surname: McNulty fullname: McNulty, Anna – sequence: 7 givenname: Nigel surname: Carrington fullname: Carrington, Nigel – sequence: 8 givenname: Heng surname: Lu fullname: Lu, Heng – sequence: 9 givenname: Melanie surname: Kingsland fullname: Kingsland, Melanie – sequence: 10 givenname: Colette surname: McGrath fullname: McGrath, Colette – sequence: 11 givenname: Phillip surname: Read fullname: Read, Phillip – sequence: 12 givenname: Mitchell surname: Starr fullname: Starr, Mitchell – sequence: 13 givenname: Beth surname: Catlett fullname: Catlett, Beth – sequence: 14 givenname: Philip surname: Cunningham fullname: Cunningham, Philip – sequence: 15 givenname: Jason orcidid: 0000-0002-1833-2017 surname: Grebely fullname: Grebely, Jason |
BookMark | eNp9kMtOwzAQRS1UJMpjxwfMDhYU7DyalF0fQJFQQaSoy2gST8DgxsF2VPELfDWpyoIVm5mR5uhK9xyyXm1qYuxU8EvBR-GVqZTsBspYJHusH4RBOkhHcdL7cx-wE-feOedC8Jgnoz77nlODXnnlYApLS-jXVHt4aTx-ENwarc1G1a8ws4okTLQxErLGeFiS89tHZSz8zXhejEHVsKANZKb1b7BCTe4Cxq3zFrXCa1i-ESyyFcwmGTwp3YVlvpVfx2y_Qu3o5HcfsZfbm-V0Pnh4vLufjh8GZRimflCmSLLCUlSjpKC4SmURSjEMpJRRIrr-MioRKY6IUyVFXBSYlFikCVIYDbEIj9j5Lrex5rPtauRr5UrSGmsyrcuDrSkRRMNhh17s0NIa5yxVeWPVGu1XLni-tZ5vree_1jv8bIebtvmf_AGs7If3 |
CitedBy_id | crossref_primary_10_1080_14737159_2023_2292645 crossref_primary_10_1186_s12879_024_08989_8 |
Cites_doi | 10.1016/j.jcv.2019.01.010 10.1016/S2214-109X(20)30505-2 10.1016/j.drugpo.2017.07.002 10.1093/cid/ciaa571 10.1016/j.drugpo.2015.05.001 10.1093/infdis/jiaa442 10.1016/j.drugpo.2018.08.011 10.1093/cid/cit263 10.1016/j.jcvp.2022.100093 10.1093/infdis/jiac049 10.3390/v14071496 10.1016/j.jhep.2023.04.019 10.1111/jvh.12929 10.1016/j.drugpo.2019.102608 10.1016/S2468-1253(22)00346-6 10.1001/jamainternmed.2022.0170 10.1016/S2468-1253(22)00355-7 10.1111/jvh.13233 10.1111/j.1360-0443.2011.03749.x 10.1136/flgastro-2016-100776 10.3390/v15020521 10.1016/j.drugpo.2022.103654 10.3390/v14112463 10.1016/S2468-1253(20)30303-4 10.1111/dar.13688 10.1016/j.drugpo.2022.103706 10.1016/j.drugpo.2023.103982 10.4269/ajtmh.17-0889 10.3390/v14071555 |
ContentType | Journal Article |
Copyright | The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023 |
Copyright_xml | – notice: The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2023 |
DBID | TOX AAYXX CITATION 7X8 |
DOI | 10.1093/ofid/ofad517 |
DatabaseName | Oxford Academic Journals (Open Access) CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: TOX name: OUP_牛津大学出版社OA刊 url: https://academic.oup.com/journals/ sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2328-8957 |
EndPage | ofad517 |
ExternalDocumentID | 10_1093_ofid_ofad517 10.1093/ofid/ofad517 |
GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX AAYXX ABEJV CITATION ITC 7X8 |
ID | FETCH-LOGICAL-c338t-c8aedfac1f97be5f8db3d162ddd471fadd4caae54e0efd15bba7cab87ae346ab3 |
IEDL.DBID | M48 |
ISSN | 2328-8957 |
IngestDate | Wed Dec 04 14:53:19 EST 2024 Fri Dec 06 04:20:58 EST 2024 Wed Aug 28 03:17:41 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | HCV DBS models of care direct-acting antivirals testing |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c338t-c8aedfac1f97be5f8db3d162ddd471fadd4caae54e0efd15bba7cab87ae346ab3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-1833-2017 0000-0002-9082-9714 |
OpenAccessLink | https://dx.doi.org/10.1093/ofid/ofad517 |
PQID | 2895712466 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_2895712466 crossref_primary_10_1093_ofid_ofad517 oup_primary_10_1093_ofid_ofad517 |
PublicationCentury | 2000 |
PublicationDate | 2023-11-01 20231101 |
PublicationDateYYYYMMDD | 2023-11-01 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US |
PublicationTitle | Open forum infectious diseases |
PublicationYear | 2023 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Catlett (2023113021491625700_ofad517-B17) 2022; 2 Eckhardt (2023113021491625700_ofad517-B30) 2022; 182 Valerio (2023113021491625700_ofad517-B4) 2022; 105 Lim (2023113021491625700_ofad517-B14) 2018; 99 Sheehan (2023113021491625700_ofad517-B27) 2023; 79 Radley (2023113021491625700_ofad517-B15) 2017; 8 Catlett (2023113021491625700_ofad517-B16) 2021; 223 Oru (2023113021491625700_ofad517-B7) 2021; 9 Trickey (2023113021491625700_ofad517-B34) 2023; 8 Valerio (2023113021491625700_ofad517-B5) 2021; 73 Mohamed (2023113021491625700_ofad517-B26) 2020; 75 Heard (2023113021491625700_ofad517-B19) Conway (2023113021491625700_ofad517-B22) 2022; 14 Valerio (2023113021491625700_ofad517-B28) 2023 Deming (2023113021491625700_ofad517-B31) 2018; 25 Bajis (2023113021491625700_ofad517-B23) 2020; 27 Jin (2023113021491625700_ofad517-B20) 2021; 6 Grebely (2023113021491625700_ofad517-B33) 2023; 114 World Health Organization (2023113021491625700_ofad517-B1) 2016 NHS England (2023113021491625700_ofad517-B25) Larney (2023113021491625700_ofad517-B29) 2022; 103 Catlett (2023113021491625700_ofad517-B13) 2022; 226 Grebely (2023113021491625700_ofad517-B32) 2023; 8 Australian Government Department of Health (2023113021491625700_ofad517-B2) Nyein (2023113021491625700_ofad517-B24) 2023; 15 Catlett (2023113021491625700_ofad517-B18) 2019; 112 Cunningham (2023113021491625700_ofad517-B12) 2021; 6 Conway (2023113021491625700_ofad517-B9) 2022; 14 Bajis (2023113021491625700_ofad517-B10) 2018; 61 Coats (2023113021491625700_ofad517-B11) 2015; 26 Treloar (2023113021491625700_ofad517-B3) 2013; 57 Harris (2023113021491625700_ofad517-B8) 2012; 107 Yousafzai (2023113021491625700_ofad517-B21) 2022; 14 Bajis (2023113021491625700_ofad517-B6) 2017; 47 |
References_xml | – volume: 112 start-page: 40 year: 2019 ident: 2023113021491625700_ofad517-B18 article-title: Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots publication-title: J Clin Virol doi: 10.1016/j.jcv.2019.01.010 contributor: fullname: Catlett – volume: 9 start-page: e431 year: 2021 ident: 2023113021491625700_ofad517-B7 article-title: Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment : a global systematic review and meta-analysis publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(20)30505-2 contributor: fullname: Oru – ident: 2023113021491625700_ofad517-B25 contributor: fullname: NHS England – volume: 47 start-page: 34 year: 2017 ident: 2023113021491625700_ofad517-B6 article-title: Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2017.07.002 contributor: fullname: Bajis – volume: 73 start-page: e69 year: 2021 ident: 2023113021491625700_ofad517-B5 article-title: Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa571 contributor: fullname: Valerio – volume: 26 start-page: 1050 year: 2015 ident: 2023113021491625700_ofad517-B11 article-title: The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2015.05.001 contributor: fullname: Coats – ident: 2023113021491625700_ofad517-B2 contributor: fullname: Australian Government Department of Health – volume: 223 start-page: 818 year: 2021 ident: 2023113021491625700_ofad517-B16 article-title: Evaluation of the Aptima HCV Quant Dx assay for hepatitis C virus RNA detection from fingerstick capillary dried blood spot and venepuncture-collected samples publication-title: J Infect Dis doi: 10.1093/infdis/jiaa442 contributor: fullname: Catlett – volume: 61 start-page: 23 year: 2018 ident: 2023113021491625700_ofad517-B10 article-title: Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2018.08.011 contributor: fullname: Bajis – volume: 57 start-page: S51 issue: Suppl 2 year: 2013 ident: 2023113021491625700_ofad517-B3 article-title: Understanding barriers to hepatitis C virus care and stigmatization from a social perspective publication-title: Clin Infect Dis doi: 10.1093/cid/cit263 contributor: fullname: Treloar – volume: 2 start-page: 100093 year: 2022 ident: 2023113021491625700_ofad517-B17 article-title: Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infection publication-title: J Clin Virol Plus doi: 10.1016/j.jcvp.2022.100093 contributor: fullname: Catlett – volume: 226 start-page: 1005 year: 2022 ident: 2023113021491625700_ofad517-B13 article-title: Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review publication-title: J Infect Dis doi: 10.1093/infdis/jiac049 contributor: fullname: Catlett – volume: 6 start-page: 533 year: 2021 ident: 2023113021491625700_ofad517-B12 article-title: Interventions to enhance testing and linkage to treatment for hepatitis C infection: a systematic review and meta-analysis publication-title: Lancet Gastroenterol Hepatol contributor: fullname: Cunningham – ident: 2023113021491625700_ofad517-B19 contributor: fullname: Heard – volume: 14 start-page: 1496 year: 2022 ident: 2023113021491625700_ofad517-B21 article-title: Time to hepatitis C RNA testing and treatment in the era of direct-acting antiviral therapy among people with hepatitis C in New South Wales, Australia publication-title: Viruses doi: 10.3390/v14071496 contributor: fullname: Yousafzai – volume: 79 start-page: 635 year: 2023 ident: 2023113021491625700_ofad517-B27 article-title: A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: the PIVOT study publication-title: J Hepatol doi: 10.1016/j.jhep.2023.04.019 contributor: fullname: Sheehan – volume: 25 start-page: 1236 year: 2018 ident: 2023113021491625700_ofad517-B31 article-title: Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: a surveillance-based propensity score matching approach publication-title: J Viral Hepat doi: 10.1111/jvh.12929 contributor: fullname: Deming – volume: 75 start-page: 102608 year: 2020 ident: 2023113021491625700_ofad517-B26 article-title: Time matters: point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2019.102608 contributor: fullname: Mohamed – volume: 8 start-page: 253 year: 2023 ident: 2023113021491625700_ofad517-B34 article-title: Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(22)00346-6 contributor: fullname: Trickey – volume: 182 start-page: 494 year: 2022 ident: 2023113021491625700_ofad517-B30 article-title: Accessible hepatitis C care for people who inject drugs: a randomized clinical trial publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2022.0170 contributor: fullname: Eckhardt – volume: 8 start-page: 204 year: 2023 ident: 2023113021491625700_ofad517-B32 article-title: A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(22)00355-7 contributor: fullname: Grebely – volume: 27 start-page: 281 year: 2020 ident: 2023113021491625700_ofad517-B23 article-title: Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: the LiveRLife study publication-title: J Viral Hepat doi: 10.1111/jvh.13233 contributor: fullname: Bajis – volume: 107 start-page: 1090 year: 2012 ident: 2023113021491625700_ofad517-B8 article-title: Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs publication-title: Addiction doi: 10.1111/j.1360-0443.2011.03749.x contributor: fullname: Harris – volume: 8 start-page: 221 year: 2017 ident: 2023113021491625700_ofad517-B15 article-title: A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland publication-title: Frontline Gastroenterol doi: 10.1136/flgastro-2016-100776 contributor: fullname: Radley – volume: 15 start-page: 521 year: 2023 ident: 2023113021491625700_ofad517-B24 article-title: Evaluation of simplified HCV diagnostics in HIV/HCV co-infected patients in Myanmar publication-title: Viruses doi: 10.3390/v15020521 contributor: fullname: Nyein – volume: 103 start-page: 103654 year: 2022 ident: 2023113021491625700_ofad517-B29 article-title: A gender lens is needed in hepatitis C elimination research publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2022.103654 contributor: fullname: Larney – volume: 14 start-page: 2463 year: 2022 ident: 2023113021491625700_ofad517-B9 article-title: Awareness of HCV status and preferences for testing and treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO pilot study publication-title: Viruses doi: 10.3390/v14112463 contributor: fullname: Conway – volume: 6 start-page: 39 year: 2021 ident: 2023113021491625700_ofad517-B20 article-title: Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(20)30303-4 contributor: fullname: Jin – year: 2023 ident: 2023113021491625700_ofad517-B28 article-title: Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: a population-based study publication-title: Drug Alcohol Rev. doi: 10.1111/dar.13688 contributor: fullname: Valerio – volume: 105 start-page: 103706 year: 2022 ident: 2023113021491625700_ofad517-B4 article-title: Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: the ETHOS Engage study publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2022.103706 contributor: fullname: Valerio – volume: 114 start-page: 103982 year: 2023 ident: 2023113021491625700_ofad517-B33 article-title: Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO pilot study publication-title: Int J Drug Policy doi: 10.1016/j.drugpo.2023.103982 contributor: fullname: Grebely – volume-title: Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis year: 2016 ident: 2023113021491625700_ofad517-B1 contributor: fullname: World Health Organization – volume: 99 start-page: 256 year: 2018 ident: 2023113021491625700_ofad517-B14 article-title: Review article: dried blood spots for global health diagnostics and surveillance: opportunities and challenges publication-title: Am J Trop Med Hyg doi: 10.4269/ajtmh.17-0889 contributor: fullname: Lim – volume: 14 start-page: 1555 year: 2022 ident: 2023113021491625700_ofad517-B22 article-title: A testing campaign intervention consisting of peer-facilitated engagement, point-of-care HCV RNA testing, and linkage to nursing support to enhance hepatitis C treatment uptake among people who inject drugs: the ETHOS Engage study publication-title: Viruses doi: 10.3390/v14071555 contributor: fullname: Conway |
SSID | ssj0001105079 |
Score | 2.3254862 |
Snippet | Abstract
Background
Dried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out... BackgroundDried blood spot (DBS) testing for hepatitis C virus (HCV) RNA provides a sampling option that avoids venepuncture and can be carried out in a... |
SourceID | proquest crossref oup |
SourceType | Aggregation Database Publisher |
StartPage | ofad517 |
Title | Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study |
URI | https://search.proquest.com/docview/2895712466 |
Volume | 10 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dSxtBEF_Ugvgi2ip-VaZQ3zy93O19CUVMbAhCUjEJ5u2Y3Z2DoFxickH9F_pXd_ZyV2oR2pd92WUe5rc785vd2RkhvuqAeYJPmROgh470s8RBN1GOpjAkQuWpsjdgtxd2hvJmFIxWRN1ttFLg_N3QzvaTGs4ez16eXi_5wH-riiGdMwqGBzRBI1oVHzz2iTa5q1sR_fK2hWmEWxbeYwYRO3ESRFUW_N8C3vinN3_eaiNdep72ltisKCNcLTHeFiuUfxTr3epR_JP42SGbFl2M59CCQZ04DsNpgQ8EbQZ68swOCq45KjbQtJnq0J9OChjYChs8wbwV_pRx17uCcQ5s_6DssAf37EXmp_D7XuQCeHdBr38P180-3I4fWZhNSHzdEcP290Gr41QtFhzNsWnh6BjJZKgbWRIpCrLYKN80Qs8Yw16LNWKkRqRAkkuZaQRKYaRRxRGSL0NU_q5Yyyc57QnQkSaO5aRLkiS6molPZhK2IS56CUraFye1YtPpspJGunwB91MLQFoBsC-Atf6PJV9qSFI-DfaJA3OaLOapZ5FlyhKGB_-x5lBs2O7xy6-FR2KtmC3oM3OMQh2XsflxuYl4HPwY_QJxvdXr |
link.rule.ids | 314,780,784,864,1604,2221,24318,27924,27925 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatitis+C+Treatment+Uptake+Following+Dried+Blood+Spot+Testing+for+Hepatitis+C+RNA+in+New+South+Wales%2C+Australia%3A+The+NSW+DBS+Pilot+Study&rft.jtitle=Open+forum+infectious+diseases&rft.au=Conway%2C+Anna&rft.au=Stevens%2C+Annabelle&rft.au=Murray%2C+Carolyn&rft.au=Prain%2C+Bianca&rft.date=2023-11-01&rft.issn=2328-8957&rft.eissn=2328-8957&rft.volume=10&rft.issue=11&rft.spage=ofad517&rft.epage=ofad517&rft_id=info:doi/10.1093%2Fofid%2Fofad517&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |